Barclays raised the firm’s price target on Biomea Fusion to $9 from $5 and keeps an Equal Weight rating on the shares. The firm is “encouraged” by the clinical hold lift on BMF-219 in diabetes. The move suggests limited FDA concern over liver enzyme elevations seen in dose escalation, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA:
- Biomea Fusion upgraded to Buy from Neutral at Rodman & Renshaw
- Truist sees fair value of $20-$50 per share after Biomea Fusion hold lifted
- Biomea Fusion says FDA lifts clinical hold on BMF-219 trials
- Short Report: Bearish bets on Comstock elevated as short-squeeze risk grows
- Biomea Fusion initiated with an Overweight at Capital One